Premium
P3‐265: Use of apoE genotyping as a pharmacogenetic biomarker in phase II disease modification trials for Alzheimer's disease
Author(s) -
Stone David J.,
Molony Cliona,
Potter William Z.
Publication year - 2010
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2010.05.1765
Subject(s) - apolipoprotein e , disease , clinical trial , medicine , placebo , pharmacogenetics , oncology , epidemiology , surrogate endpoint , allele , alzheimer's disease , cognitive decline , genotype , dementia , genetics , pathology , biology , alternative medicine , gene